Surgery
Surgical VTE Prophylaxis
NICE NG89 — risk-stratify all surgical inpatients, mechanical + pharmacological prophylaxis, extended duration in selected.
Source: NICE NG89 (2018)
Step 1 of ~2
info
Risk Assessment (NICE NG89)
Assess ALL surgical inpatients on admission + reassess at 24h + after change.
VTE risk factors: surgical >90 min (or >60 min lower limb / pelvis), age >60, previous VTE, malignancy, BMI >30, hormonal therapy, pregnancy / postpartum, thrombophilia, hospitalised.
Bleeding risk factors: active bleeding, acquired coagulopathy, on anticoagulants, lumbar puncture / spinal anaesthesia within 4h, severe HTN, untreated bleeding disorder, severe thrombocytopenia, neurological / spinal surgery.
Balance VTE vs bleeding risk.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Betrixaban (Extended VTE Prophylaxis — Medical Patients) · Oral Factor Xa Inhibitor (DOAC — Extended Duration)
- Cefuroxime · Second-Generation Cephalosporin — Respiratory / Surgical Prophylaxis
- Posaconazole · Extended-Spectrum Triazole — Aspergillus / Mucor / Prophylaxis in Immunocompromised
- Cefazolin · First-Generation Cephalosporin (Surgical Prophylaxis)
- Palivizumab · RSV Prophylaxis — Monthly Monoclonal Antibody (High-Risk Infants)
- Cefazolin (Surgical Prophylaxis) · 1st Generation Cephalosporin (Surgical Antibiotic Prophylaxis)
Pathways
- Major Trauma — Primary Survey (ATLS) · ATLS 10th Edition; JRCALC; NICE NG39
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Burns — TBSA Estimation & Fluid Resuscitation · British Burn Association; EMSB; RCEM 2024
- Lower Gastrointestinal Bleed · NICE; BSG; ACPGBI — Commissioning Guide
- Acute Pancreatitis · NICE; IAP/APA; ACPGBI — CG104
- Hypertrophic Pyloric Stenosis · BAPS / RCPCH
Decision support only. Always apply local guidelines and clinical judgement.